Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Market Closed 12-20 16:00:00 EST

4.95

-0.12

-2.37%

盘后4.99

+0.04+0.81%

18:37 EST

High5.25	Low4.92	Vol436.94K
Open4.93	D1 Closing5.07	Amplitude6.51%
Mkt Cap159.37M	Tradable Cap88.28M	Total Shares32.20M
T/O2.20M	T/O Rate2.45%	Tradable Shares17.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":4.95,"timestamp":1734728400000,"preClose":5.07,"halted":0,"volume":436944,"hourTrading":{"tag":"盘后","latestPrice":4.99,"preClose":4.95,"latestTime":"18:37 EST","volume":1579,"amount":7719.695,"timestamp":1734737872952},"delay":0,"floatShares":17833358,"shares":32195345,"eps":-1.287523,"marketStatus":"Market Closed","change":-0.12,"latestTime":"12-20 16:00:00 EST","open":4.93,"high":5.25,"low":4.92,"amount":2201110.774411,"amplitude":0.065089,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.287523,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":5.07,"preHourTrading":{"tag":"盘前","latestPrice":5.15,"preClose":5.07,"latestTime":"09:16 EST","volume":878,"amount":4545.969939,"timestamp":1734704161169},"postHourTrading":{"tag":"盘后","latestPrice":4.99,"preClose":4.95,"latestTime":"18:37 EST","volume":1579,"amount":7719.695,"timestamp":1734737872952},"volumeRatio":0.26620673073482465,"impliedVol":1.783,"impliedVolPercentile":0.5655},"requestUrl":"/m/hq/s/SGMT/tweets","defaultTab":"tweets","newsList":[{"id":"2491232501","title":"Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2491232501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491232501?lang=en_us&edition=fundamental","pubTime":"2024-12-15 22:16","pubTimestamp":1734272203,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmt/sagimet-biosciences/news/sagimet-biosciences-nasdaqsgmt-is-in-a-good-position-to-deli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2210149790.SGD","TSYW.SI","PSQ","BK4585","LU2095319765.USD","USAW.SI","NVIW.SI","IE00B64PRP62.GBP","NDAQ","BK4112","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","SQQQ","LU2210150020.SGD","QLD",".IXIC","SGMT","MNQmain","USJW.SI","QID","NQmain","IE00BKPKM429.USD","TQQQ","BK4139"],"gpt_icon":1},{"id":"2489781269","title":"Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489781269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489781269?lang=en_us&edition=fundamental","pubTime":"2024-12-08 16:40","pubTimestamp":1733647206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chromadex (CDXC – Research Report) and Sagimet Biosc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","SGMT","BK4121","CDXC","BK4139","BK4137"],"gpt_icon":0},{"id":"2489237474","title":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2489237474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489237474?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:02","pubTimestamp":1733500955,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'** Drug developer Sagimet Biosciences' SGMT.O shares rise 8.4% to $5.05** Oppenheimer starts coverage with \"outperform\" rating and PT at $30 — a 543.8% premium to Thursday's close of $4.66** Brokerage sees \"underappreciated opportunity\" in co's lead experimental drug, denifanstat, being developed to treat metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** The MASH market is dominated by Madrigal Pharmaceuticals' MDGL.O Rezdiffra** \"We see SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve,\" brokerage says ** Oppenheimer expects risk-adjusted peak total revenues of ~$1.9 bln for denifanstat in 2040      ** Including session's move, stock down 8.5% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3N3N70WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","SGMT"],"gpt_icon":0},{"id":"2489252350","title":"Oppenheimer Initiates Sagimet Biosciences at Outperform With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2489252350","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489252350?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:51","pubTimestamp":1733493115,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2489814052","title":"Sagimet Biosciences Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489814052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489814052?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:27","pubTimestamp":1733488020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 07:27 ET (12:27 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","SGMT"],"gpt_icon":0},{"id":"2489247601","title":"Sagimet Biosciences Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2489247601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489247601?lang=en_us&edition=fundamental","pubTime":"2024-12-06 14:28","pubTimestamp":1733466501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N7028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2489153644","title":"Sagimet Biosciences initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489153644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489153644?lang=en_us&edition=fundamental","pubTime":"2024-12-06 05:17","pubTimestamp":1733433443,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $30 price target Published first on TheFly – the ultimat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2486183077","title":"Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486183077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486183077?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987446/0/en/Sagimet-Biosciences-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","SGMT","HCSG","BK4139"],"gpt_icon":0},{"id":"2484903475","title":"Sagimet Biosciences participates ik,on No","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903475?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:00","pubTimestamp":1732050020,"startTime":"0","endTime":"0","summary":"Biotech Analyst Agrawal holds a conference call with CEO Happel and CFO Chauche on November 22 at 12 pm hosted by Cantor Fitzgerald. ():(https://ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT","GRO"],"gpt_icon":0},{"id":"2484962214","title":"Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484962214","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484962214?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients. Both artificial intelligence  and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity. SAN MATEO, Calif., Nov. 18, 2024  -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase  inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease  - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.GLP1 receptor agonist population: 42% denifanstat  vs 0% placebo (n=4) . Type 2 diabetes population: 40% denifanstat  vs 19% placebo  . PNPLA3 I148 carrier population: 30% denifanstat  vs 6% placebo  ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vN9syB.4joRY7zqfsihqcg--~B/aD05NDE7dz0yNTYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f62671a6941ad62a5569bf4eb2a2514a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vN9syB.4joRY7zqfsihqcg--~B/aD05NDE7dz0yNTYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f62671a6941ad62a5569bf4eb2a2514a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sagimet-biosciences-presents-clinical-denifanstat-130000389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SHG","BK4207","SGMT"],"gpt_icon":0},{"id":"2483584337","title":"Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483584337","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483584337?lang=en_us&edition=fundamental","pubTime":"2024-11-16 03:46","pubTimestamp":1731699960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 14:46 ET (19:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2483092013","title":"Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483092013?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:15","pubTimestamp":1731687310,"startTime":"0","endTime":"0","summary":"Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2483394225","title":"Sagimet Biosciences Advances MASH Treatment with Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2483394225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483394225?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:34","pubTimestamp":1731645291,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q3 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-denifanstat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-denifanstat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2483490367","title":"Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483490367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483490367?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:15","pubTimestamp":1731636908,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A (SGMT) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral. Ritu Baral has given her Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2483457808","title":"Sagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483457808","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483457808?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:32","pubTimestamp":1731591156,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 28.57 percent decrease over losses of $(0.35) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41971495/sagimet-biosciences-q3-eps-0-45-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2483387725","title":"Sagimet Biosciences Inc: Anticipated Cash Runway Through 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483387725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483387725?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUACBJSK5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2483877540","title":"Press Release: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877540?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Denifanstat received Breakthrough Therapy designation from FDA for MASH. Successful completion of end-of-Phase 2 interactions with FDA on the development of denifanstat for MASH; Phase 3 program initiation expected by end of 2024. Anticipated cash runway through 2025, with cash, cash equivalents and marketable securities totaling $170.0 million as of September 30, 2024. \"As we approach the end of 2024, the Sagimet team remains focused on advancing denifanstat towards a pivotal Phase 3 program in MASH,\" said David Happel, Chief Executive Officer of Sagimet. \"The publication of our Phase 2b FASCINATE-2 study results in a highly regarded Lancet journal highlighted denifanstat's strong efficacy and tolerability data and its highly differentiated mechanism of action which enables denifanstat to improve the key drivers of MASH: fat accumulation, inflammation, and fibrosis. In addition, we are proud to have recently received Breakthrough Therapy designation for denifanstat in MASH from the FD","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2482084528","title":"Sagimet Biosciences Inc : UBS Initiates Coverage With Buy Rating and Target Price  $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2482084528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482084528?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:25","pubTimestamp":1731425109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nAZN2LPJ6U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2482034937","title":"UBS Initiates Sagimet Biosciences at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2482034937","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482034937?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:17","pubTimestamp":1731413825,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average outperform rating and a price target range of $6 to $67, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic resear","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT"],"gpt_icon":0},{"id":"2482420129","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2482420129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482420129?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:00","pubTimestamp":1731322800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Angi Inc Class A                                3Q       .00       AMC. ·Global Ship Lease                                3Q      2.41   8:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAVE","CRDL","CLRB","AXSM","FLNG","IKT","NRGV","AZN","OBIO","RVPH","ATER","CHGG","FIHL","CAE","TSVT","CCLD","ASRT","CNNE","XP","ARMK","XGN","DAVA","GAUZ","LAZR","SGMT","GENI","DHT","TWKS","DHX","AVTE","DDI","CNTA","EQ","ATAI","FTCI","KEP","CRVO","EARN","ABSI","CYTH","GATO","MLYS","ICL","NOTE","BLFS","FBRX","IAC","ABOS","INTS","AMTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0.1276},{"period":"1month","weight":0.0951},{"period":"3month","weight":0.5764},{"period":"6month","weight":0.2595},{"period":"1year","weight":-0.1223},{"period":"ytd","weight":-0.0867}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction